Wang Yingyi

Research focus: Precision diagnosis and treatment of lung cancer, with a focus on postoperative adjuvant therapy and advanced comprehensive treatment of EGFR mutation-positive non-small cell lung cancer.

Cutting-edge technology: Led the world's first prospective clinical study on adjuvant therapy after surgery for stage IB and high-risk stage IA EGFR mutation-positive non-small cell lung cancer; participated in rewriting international guidelines for the treatment of unresectable stage III non-small cell lung cancer with EGFR-sensitive mutations in 2024. Created the precision diagnosis and treatment system of the Department of Oncology at Peking Union Medical College Hospital; chief editor of the textbook "Precision Treatment of Cancer". The average survival rate of patients with advanced lung cancer far exceeds the international average by 20 percentage points.

Areas of expertise: Lung cancer (diagnosis of early-stage lung cancer and pulmonary nodules, comprehensive management of advanced lung cancer chemotherapy/targeted therapy/immunotherapy), thoracic tumors.

Academic Highlights and Core Values: Chief Physician, Professor, and Postgraduate Supervisor in the Department of Medical Oncology. Expert Reviewer for the Beijing Municipal Science and Technology Commission; Vice Chairman of the Professional Committee on Adverse Event Management of Immunotherapy of the Beijing Cancer Prevention and Treatment Association; Vice Chairman of the Expert Committee on Lung Cancer Diagnosis and Treatment of the Beijing Health Promotion Association. Published nearly 50 SCI papers as first/corresponding author. Received the Peking Union Medical College Hospital Medical Achievement Award three times between 2017 and 2021; won the first prize in the National Micro-Lesson Teaching Competition for Higher Education Institutions in 2011; and was named an "Excellent Teacher" by Peking Union Medical College Hospital in 2022.

Qiu Guixing

Academician , specializing in the etiology of spinal deformities and PUMC classification

Research areas: Clinical and basic research on spinal deformities, etiology and classification system of idiopathic scoliosis.

Cutting-edge technologies: The PUMC (Peking Union Medical College Classification) of idiopathic scoliosis was proposed, winning the second prize of the National Science and Technology Progress Award. The relationship between the TBX gene and the pathogenesis of congenital scoliosis was discovered, and the research was published in the New England Journal of Medicine.

Specializes in treating: scoliosis, kyphosis, and degenerative spinal diseases.

Academic Highlights and Core Values: Academician of the Chinese Academy of Engineering, Chairman of the Orthopedics Branch of the Chinese Medical Association, and former Director of the Department of Orthopedics at Peking Union Medical College Hospital. The PUMC classification is the most influential original contribution in the field of scoliosis in China, and the discovery of the TBX gene has propelled the research on the etiology of congenital scoliosis to the international forefront.